

ASX APPENDIX 4D

HALF-YEAR FINANCIAL REPORT TO 30 JUNE 2018

1. DETAILS OF REPORTING PERIOD				
Name of Entity	G Medical Innovations Holdings Ltd (“the Company”)			
ARBN	617 204 743			
Reporting Period	30 June 2018			
Previous Corresponding Period	30 June 2017			
2. RESULTS FOR ANNOUNCEMENT TO THE MARKET				
	30 June 2018 US\$'000	30 June 2017 US\$'000	Increase/ (decrease) %	Amount change US\$
Revenues from ordinary activities	1,001	-	100%	1,001
Profit/(Loss) after tax from ordinary activities attributable to members	(8,509)	(21,740)	(61)%	13,231
Profit/(Loss) after tax attributable to members	(8,509)	(21,740)	(61)%	13,231
			Amount Per Security	Franked Amount Per Security
Final Dividend			Nil	Nil
Interim Dividend			Nil	Nil
Previous Corresponding Period			Nil	Nil
Record Date for Determining Entitlements	Not Applicable			

Commentary on results:

G Medical Innovations Holdings Ltd (the Company) reports on half year results as of 30 June 2018. The Company had a net loss of US\$ 8.509 million versus US\$ 21.740 million in the comparable period of 2017.

The Company generated first revenues of US\$ 1.001 million, which were offset by the following operating expenses:

R&D, S&M and G&A expenses went up from US\$ 3.136 million in H1 2017 to US\$ 9.067 million. That includes:

- Expenses of US\$ 0.970 million attributed to the amortization of intangible assets while acquiring CardioStaff (renamed G Medical Diagnostic Services).
- From the balance of approximately \$5.000 million, about US\$ 3.200 million is attributed to CardioStaff activities in the US which was purchased close to the end of 2017. The rest is attributed to other operational expenses incurred to meet the Company's development (including FDA and CFDA regulatory requirements) and business goals.

3. NET TANGIBLE ASSETS PER SHARE		
	30 June 2018	30 June 2017
Net tangible asset backing per ordinary security	0.002 cents	0.035 cents

4. DETAILS OF ENTITIES OVER WHICH CONTROL HAS BEEN GAINED OR LOST DURING THE PERIOD

Control gained over entities		
Name of entity (or group of entities)		N/A
Date control gained		N/A
Contribution of such entities to the reporting entity's profit/(loss) from ordinary activities during the period (where material)		N/A
Consolidated profit/(loss) from ordinary activities of the controlled entity (or group of entities) whilst controlled during the whole of the previous corresponding period (where material)		N/A
Loss of control over entities		
Name of entity (or group of entities)		N/A
Date control lost		N/A
Contribution of such entities to the reporting entity's profit/(loss) from ordinary activities during the period (where material)		N/A
Consolidated profit/(loss) from ordinary activities of the controlled entity (or group of entities) whilst controlled during the whole of the previous corresponding period (where material)		N/A

5. DIVIDEND DETAILS

No dividend has been paid or recommended to be paid for the half-year ended 30 June 2018.

6. DETAILS OF DIVIDEND REINVESTMENT PLANS

Not Applicable

7. DETAILS OF ASSOCIATE AND JOINT VENTURE ENTITIES

Not Applicable

8. FOREIGN ENTITIES

The interim financial statements are prepared in accordance with International Financial Reporting Standards ("IFRS").

9. AUDIT

The interim financial information for the six-month period ended 30 June 2018 presented has been reviewed and are not subject to any audit dispute or qualification.

Dr Yacov Geva
 President and Chief Executive Officer
 August 30, 2018

